| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | 6 | 18 | 8 | 4 | — | — | 2 | 7 | 7 | 1 | — | — |
| total | individual payouts | |
|---|---|---|
| 2025 | ‡‡‡ |
|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 134.34 | 111.00 | 57.05 | 21.99 |
| Receivables | 1.35 | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 138.37 | 113.07 | 58.59 | 22.89 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.34 | 3.04 | 0.75 | 1.94 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 19.38 | 15.18 | 36.15 | 7.86 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | 21.00 | — | — |
—
|
| ’24 | 0.74 | 1.14 | — | — |
1.89
|
| ’23 | 4.46 | 8.08 | 5.90 | 1.50 |
19.94
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (10.60) | 6.63 | — | — |
—
|
| ’25 | (18.95) | (15.16) | (15.16) | (11.02) |
(60.29)
|
| ’24 | (15.30) | (14.18) | (12.46) | (14.25) |
(56.19)
|
| ’23 | (9.90) | (10.92) | (7.21) | (4.58) |
(32.61)
|
| ’22 | (13.95) | (0.30) | (14.47) | (11.87) |
(40.60)
|
| ’21 | (7.33) | (10.46) | (12.42) | (12.67) |
(42.88)
|
| ’20 | (3.40) | (4.29) | (4.92) | (6.01) |
(18.62)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (10.60) | 7.05 | — | — |
—
|
| ’25 | (18.95) | (15.16) | (15.16) | (11.02) |
(60.29)
|
| ’24 | (15.41) | (14.19) | (12.46) | (14.37) |
(56.44)
|
| ’23 | (10.07) | (11.10) | (7.43) | (4.78) |
(33.38)
|
| ’22 | (13.98) | (1.41) | (16.43) | (12.39) |
(44.21)
|
| ’21 | (7.34) | (10.57) | (12.52) | (12.94) |
(43.37)
|
| ’20 | (3.85) | (4.34) | (4.98) | (6.02) |
(19.18)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.28) | 0.08 | — | — |
—
|
| ’25 | (0.40) | (0.40) | (0.36) | (0.20) |
(1.33)
|
| ’24 | (0.39) | (0.43) | (0.38) | (0.46) |
(1.63)
|
| ’23 | (0.34) | (0.14) | (0.23) | (0.33) |
(1.05)
|
| ’22 | (0.56) | (0.53) | (0.40) | (0.39) |
(1.86)
|
| ’21 | (83.36) | (3.82) | (0.51) | (0.66) |
(10.94)
|
| ’20 | — | — | (0.21) | — |
(0.98)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡‡ | 1.39 | 1.57 | 1.38 | 0.56 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 12.86 | 4.57 | 8.19 | 2.38 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | 46 | 47 | 46 | 39 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.36 | 0.42 | 0.04 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | 16.40 | 19.94 | 1.89 | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 100.00% | 100.00% | 100.00% | — | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (53.81) | (37.37) | (70.51) | (60.82) | — | — | — |
EBT
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | (328.09%) | (187.37%) | (3,740.85%) | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (53.81) | (37.37) | (70.51) | (60.82) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.31 | 1.82 | 1.81 | 1.63 | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.57 | 0.56 | 0.04 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.86) | (1.05) | (1.63) | (1.32) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.41) | (0.91) | (1.30) | (1.31) | ‡‡‡‡‡ | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.13) | (0.02) | (0.01) | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.53) | (0.94) | (1.30) | (1.31) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.24 | 3.12 | 1.69 | 0.54 | — | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 28.86 | 35.65 | 43.33 | 46.02 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | 0.00 | 8.29 | 6.91 | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | 0.48 | 1.49 | 0.87 | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | 0.00 | 3.36 | (1.88) | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | 1.25 | (2.01) | 0.31 | — | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (40.60) | (32.61) | (56.19) | (60.29) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.61) | (0.77) | (0.25) | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (44.21) | (33.38) | (56.44) | (60.29) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 116.21 | 118.99 | 97.89 | 22.44 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 14.68 | 32.66 | 26.10 | — | — | — | — |
Total Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (114.63) | (101.69) | (84.90) | (57.05) | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 122.34 | 111.37 | 73.39 | 24.81 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (31.70%) | (22.30%) | (46.74%) | (61.96%) | — | — | — |
ROA
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (454.65%) | (261.32%) | 0.00% | 0.00% | — | — | — |
ROIC
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (39.12%) | (31.98%) | (76.33%) | (123.88%) | — | — | — |
ROE
|
Werewolf Therapeutics (HOWL), a clinical-stage biotech innovating the INDUKINE platform for targeted immune activation in cancer and inflammatory diseases, trades at deeply depressed levels in mid-February 2026, down over 94% from its 2021 IPO peak amid biotech euphoria. The stock’s rollercoaster mirrors sector woes: early hype from cell therapy buzz gave way to trial delays, a 91% revenue plunge to $1.89 million in 2024, relentless dilution (shares up 134%), and worsening cash burn, with free cash flow per share dropping 42% YoY despite a solid $85 million net cash position.
Financials highlight classic pre-commercial risks—perfect gross margins but EBT margins cratering to -37% and net losses deepening 89%—yet analyst forecasts eye a 430% revenue rebound to $10 million in 2025, fueled by potential pipeline milestones like WTX-124 trials or autoimmune pivots. Insider activity leans bearish with $6.53 million in sells dwarfing a single $487k buy, but Wall Street remains cautiously optimistic, with mean price targets implying 515% upside (highs over 1,400%).
In this high-stakes biotech narrative, HOWL’s fortress balance sheet and immunotherapy tailwinds offer turnaround whispers, but execution on catalysts amid FDA risks and competition will determine if it howls back or fades—tempting for risk-tolerant investors eyeing historical survivors.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.